![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Kite Pharma, Inc. | NASDAQ:KITE | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 179.79 | 107.00 | 179.99 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
(Rule 14d-101)
(Amendment No. 5)
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
Kite Pharma, Inc.
(Name of Subject Company)
Kite Pharma, Inc.
(Name of Person Filing Statement)
COMMON STOCK, PAR VALUE $0.001 PER SHARE
(Title of Class of Securities)
49803L109
(CUSIP Number of Class of Securities)
Arie Belldegrun, M.D.
President and Chief Executive Officer
Kite Pharma, Inc.
2225 Colorado Avenue
Santa Monica, California 90404
(310) 824-9999
(Name, address and telephone numbers of person authorized to receive notices and communications
on behalf of the persons filing statement)
With copies to:
Alison S. Ressler
Eric M. Krautheimer
Sullivan & Cromwell LLP
1888 Century Park East
Los Angeles, California 90067
(310) 712-6600
☐ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
This Amendment No. 5 (this Amendment ) to Schedule 14D-9 amends and supplements the Schedule 14D-9 previously filed by Kite Pharma, Inc., a Delaware corporation (the Company ) with the U.S. Securities and Exchange Commission on September 5, 2017, and amended on September 7, 2017, September 8, 2017, September 15, 2017 and September 25, 2017 (as amended, the Solicitation/Recommendation Statement ), with respect to the tender offer by Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead Sciences, Inc., a Delaware corporation, to purchase all outstanding shares of the Companys common stock, par value $0.001 per share. Capitalized terms used in this Amendment but not defined herein shall have the respective meaning given to such terms in the Solicitation/Recommendation Statement. The information set forth in the Solicitation/Recommendation Statement remains unchanged and is incorporated herein by reference, except that such information is hereby amended or supplemented to the extent specifically provided herein.
ITEM 8. | ADDITIONAL INFORMATION. |
Item 8 of the Solicitation/Recommendation Statement is hereby amended and supplemented as follows:
(a) The second paragraph under the heading entitled Antitrust Compliance in Item 8, as earlier amended by the Company on September 8, 2017, is amended and restated as follows:
On September 8, 2017, each of the Company and Gilead filed Premerger Notification and Report Forms under the HSR Act with the FTC and the Antitrust Division in connection with the acquisition of Shares pursuant to the Offer. The waiting period applicable to the Offer under the HSR Act expired at 11:59 p.m. New York City time on September 25, 2017. Accordingly, the condition of the Offer relating to the waiting period applicable to the Offer under the HSR Act having expired or been terminated has been satisfied.
(b) The following paragraph is added after the last paragraph under the heading entitled Antitrust Compliance in Item 8:
On September 26, 2017, the Company and Gilead issued a joint press release announcing the expiration of the required waiting period under the HSR Act with respect to the Offer, a copy of which is attached hereto as Exhibit (a)(5)(O).
ITEM 9. | EXHIBITS. |
Item 9 of the Solicitation/Recommendation Statement is hereby amended and supplemented by adding the following exhibit:
Exhibit No. |
Description |
|
(a)(5)(O) | Joint Press Release issued by Kite Pharma, Inc. and Gilead Sciences, Inc., dated September 26, 2017. |
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
KITE PHARMA, INC. | ||||||||
Dated: September 26, 2017 | By: |
/s/ Arie Belldegrun |
||||||
Name: | Arie Belldegrun, M.D. | |||||||
Title: | President and Chief Executive Officer |
1 Year KITE PHARMA, INC. Chart |
1 Month KITE PHARMA, INC. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions